PURPOSE: To provide a chimera antibody which is prepared by linking chimera antibody Fab fragments to each other chemically, thus is increased in retention in vivo, improved in accumulation to the target site and increased in accumulation in tumors by binding with an antitumor agent, and is ...
OLIGOMER OF FAB FRAGMENT OF CHIMERA ANTIBODY 专利名称：OLIGOMER OF FAB FRAGMENT OF CHIMERA ANTIBODY 发明人：KAMIGAKI TAKASHI,神垣 隆,OTANI WATARU,大谷 渡,OKUBO MASAHIRO,大久保 雅 啓,OMURA TAKAO,大村 孝男 申请号：JP特願平6-208225 申请日：19940810 公开号：JP特開平8-53499A 公开日：19960227 专利...
Exon 7 fragment of the p53 Gene Spundana Malla1, Karteek Kadimisetty1,You-Jun Fu1, Dharamainder Choudhary2, John B. Schenkman3 & James F. Rusling1,2,4,5 Methylation of cytosine (C) at C-phosphate-guanine (CpG) sites enhances reactivity of DNA towards electrophile...
Growth control of genetically modified cells using an antibody/c-Kit chimera(CELL AND TISSUE ENGINEERING) Gene therapy has been regarded as an innovative potential treatment against serious congenital diseases. However, applications of gene therapy remain limit... Kaneko,Etsuji,Kawahara,... - 《Journ...
The structure of the chimera was solved by molecular replacement using data to a 3.3-Å resolution. Computation of rotation and translation functions using E. coli BamB as a search model led to an unambiguous solution. After fixing the BamB position in the crystal, similar calculations using a...
After replacement of the A8 enhancer region of the neuropathogenic chimera with the enhancer region of non-neuropathogenic 57, viral titer in the brain was reduced by two orders of magnitude. However, the A8 enhancer region was not responsible for the induction of spongiosis. The region ...
3D structures were then displayed and presented using Chimera52. For the case of imaging Fab fragment, cryo-EM images were obtained from Titan Krios with VPP with defocusing. A stack of 956 movies was obtained with VPP and defocusing34, pre-processed with MotionCorr2 and Gctf for CTF ...
https://github.com/bptlab/chimera. 2. http://smile-project.de/smile-projekt/. 3. An overview of all possible state transitions can be found in [20]. References van der Aalst, W.M.P., Berens, P.J.S.: Beyond workflow management: product-driven case handling. In: Proceedings of the...
1A and 2). Substrate utilization was determined by expressing recombinant chimeras in COS-7 cells, which maintain acceptor substrate precursors for surface-localized Lex, sLex, Lea, and sLea epitopes (6, 21) and characterizing the chimera-determined cell surface glycosylation patterns of the ...
or that of IgG1 which has no ADCC (antibody-dependent cell-mediated cytotoxicity) after amino acid mutation. The variant is preferably a heavy chain constant region mutation which causes ADCC attenuation or deficiency, and more preferably N297A, L234A, L235A of IgG1, IgG2/4 chimera, and ...